Glutamate receptor ionotropic NMDA type subunit 2D (GRIN2D) (GRIN2D)

The Glutamate receptor ionotropic NMDA type subunit 2D (GluN2D) is a critical component of the N-methyl-D-aspartate (NMDA) receptor, a ligand-gated ion channel essential for excitatory neurotransmission and synaptic plasticity in the mammalian brain [1, 2]. Encoded by the GRIN2D gene, this subunit is distinguished by its unique expression profile, predominantly found in the diencephalon, midbrain, and specific interneuron populations, and its distinct biophysical properties, such as low conductance and very slow deactivation kinetics [2, 3]. These characteristics allow GluN2D-containing receptors to mediate prolonged excitatory currents, playing a vital role in regulating neuronal excitability and circuit maturation [3]. Pathogenic variants in the GRIN2D gene are clinically linked to developmental and epileptic encephalopathy (DEE46), characterized by early-onset seizures and profound developmental delay [4]. Furthermore, GluN2D is implicated in the pathophysiology of schizophrenia and Parkinson's disease, making it a target of interest for therapeutic modulation [2, 5]. Pharmacological agents interacting with this target include non-selective NMDA antagonists like ketamine and memantine, as well as experimental subunit-selective modulators designed to fine-tune glutamatergic signaling with reduced side effects [3, 5].

Other names

GluN2DNR2DN-methyl-D-aspartate receptor subunit 2DNMDAR2DEB11

Drugs targeting the GluN2D subunit typically act as non-competitive pore blockers, competitive antagonists at the glutamate binding site, or negative/positive allosteric modulators that alter the channel's gating properties and calcium permeability [2, 5].